PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10357564-11	1999	Comparison of cDNA expression arrays hybridized with thalidomide-treated LNCaP cDNA probes suggests that thalidomide may up- or downregulate expression of angiogenesis-related genes, i.e., vitronectin, but these differential effects require further verification.	Thalidomide	105-116	vitronectin	Homo sapiens	189-200	
10357564-13	1999	Furthermore, preliminary data from cDNA nucleic acid arrays of thalidomide-treated LNCaP cells suggest that thalidomide upregulates a potential angiogenic modulatory protein, the vitronectin precursor, which may eventually link thalidomide"s antiangiogenic activity with modulation of angiogenic vascular integrin pathways.	Thalidomide	63-74	vitronectin	Homo sapiens	179-190	
10357564-13	1999	Furthermore, preliminary data from cDNA nucleic acid arrays of thalidomide-treated LNCaP cells suggest that thalidomide upregulates a potential angiogenic modulatory protein, the vitronectin precursor, which may eventually link thalidomide"s antiangiogenic activity with modulation of angiogenic vascular integrin pathways.	Thalidomide	108-119	vitronectin	Homo sapiens	179-190	
10357564-13	1999	Furthermore, preliminary data from cDNA nucleic acid arrays of thalidomide-treated LNCaP cells suggest that thalidomide upregulates a potential angiogenic modulatory protein, the vitronectin precursor, which may eventually link thalidomide"s antiangiogenic activity with modulation of angiogenic vascular integrin pathways.	Thalidomide	108-119	vitronectin	Homo sapiens	179-190